Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22154560 | 1.00 | CTSV (0.48) | CTSVCTSLALDH1A1POLBABCB1 | |
| SCHEMBL22154802 | 0.92 | MYC (0.45) | CTSVCTSLALDH1A1POLBABCB1 | |
| Hydrochloric Acid SCHEMBL7036468 | 0.83 | CTSV (0.50) | CTSVCTSLALDH1A1POLBABCB1 | |
| Hydrochloric Acid SCHEMBL7036477 | 0.83 | CTSV (0.50) | CTSVCTSLALDH1A1POLBABCB1 | |
| SCHEMBL22154247 | 0.82 | BCL2 (0.47) | CTSVCTSLPDCD1CD274 | |
| SCHEMBL28642378 | 0.82 | BCL2 (0.47) | CTSVCTSLPDCD1CD274 | |
| SCHEMBL10410167 | 0.75 | CTSV (0.59) | CTSVCTSLALDH1A1POLBABCB1 | |
| SCHEMBL3599069 | 0.75 | POLB (0.54) | CTSVCTSLALDH1A1POLBABCB1 | |
| SCHEMBL28543611 | 0.75 | CTSV (0.56) | CTSVCTSLALDH1A1POLBABCB1 | |
| SCHEMBL4126272 | 0.75 | CTSV (0.58) | CTSVCTSLALDH1A1POLBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118027137-A | Tubulysin and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | CTSV 2759/4885CTSL 2986/4885ALDH1A1 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.